STOCK TITAN

[Form 4] Performant Healthcare Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Performant Healthcare (PHLT): Director Form 4 tied to merger cash-out. A company director reported a transaction dated 10/21/2025 in connection with the closing of the merger under the July 31, 2025 Merger Agreement. Immediately prior to the effective time, each share of Performant common stock was canceled and converted into the right to receive $7.75 in cash per share, without interest and subject to applicable withholding taxes.

The filing shows the reporting person’s common stock position moved to 0 shares beneficially owned following the transaction. The event reflects the share conversion mechanics at closing; the company became a wholly owned subsidiary of Continental Buyer, Inc.

Performant Healthcare (PHLT): Direttore Form 4 legato al liquidamento dell'acquisizione. Un amministratore della società ha riportato una operazione datata 21/10/2025 in relazione alla chiusura della fusione ai sensi dell'accordo di fusione del 31 luglio 2025. Immediatamente prima dell'orario effettivo, ogni azione comune di Performant è stata annullata e convertita nel diritto a ricevere $7.75 per azione, senza interessi e soggetto a ritenute fiscali applicabili.

La dichiarazione mostra che la posizione azionaria comune del soggetto che riporta è passata a 0 azioni possedute beneficiariamente dopo la transazione. L'evento riflette la meccanica di conversione delle azioni al momento della chiusura; la società è diventata una filiale interamente controllata di Continental Buyer, Inc.

Performant Healthcare (PHLT): Director Form 4 vinculado al cobro en efectivo de la fusión. Un director de la empresa reportó una transacción con fecha 21/10/2025 relacionada con el cierre de la fusión bajo el Acuerdo de Fusión del 31 de julio de 2025. Inmediatamente antes de la hora efectiva, cada acción común de Performant fue cancelada y convertida en el derecho a recibir $7.75 en efectivo por acción, sin intereses y sujeto a las retenciones fiscales correspondientes.

El informe muestra que la posición de acciones comunes de la persona reportante pasó a 0 acciones beneficiosamente poseídas tras la operación. El evento refleja la mecánica de conversión de acciones en el cierre; la empresa se convirtió en una filial 100% de Continental Buyer, Inc.

Performant Healthcare (PHLT): 이사 Form 4가 합병 현금화와 연결됨. 한 회사 이사는 2025년 10월 21일자로 합병 체결에 따른 거래를 보고했습니다. 2025년 7월 31일 합병 계약에 따라. 유효 시점 직전, Performant 보통주의 모든 주식은 취소되어 주당 $7.75 현금 수령 권리로 전환되며 이자는 없고 해당 원천징수세의 적용을 받습니다.

보고서는 보고자의 보통주 포지션이 거래 후 소유 주식 0주로 이동했음을 보여줍니다. 이 이벤트는 종가 시 주식 전환 메커니즘을 반영합니다; 회사는 Continental Buyer, Inc.의 완전한 자회사가 되었습니다.

Performant Healthcare (PHLT) : Formulaire 4 du directeur lié au rachat par fusion. Un administrateur de la société a déclaré une opération datée du 21/10/2025 dans le cadre de la clôture de la fusion sous l'accord de fusion du 31 juillet 2025. Juste avant l'heure effective, chaque action ordinaire de Performant a été annulée et convertie en droit de recevoir $7.75 en espèces par action, sans intérêts et sous réserve des impôts à la source applicables.

Le dépôt montre que la position d'actions ordinaires de la personne déclarant est passée à 0 actions détenues par le bénéficiaire après la transaction. L'événement reflète les mécanismes de conversion des actions à la clôture; la société est devenue une filiale en propriété exclusive de Continental Buyer, Inc.

Performant Healthcare (PHLT): Direktor Form 4 im Zusammenhang mit Barabfindung bei Fusion. Ein Vorstand des Unternehmens meldete eine Transaktion datiert auf den 21.10.2025 im Zusammenhang mit dem Abschluss der Fusion gemäß dem Fusionsabkommen vom 31. Juli 2025. Unmittelbar vor dem Wirksamkeitszeitpunkt wurde jede Stammaktie von Performant storniert und in das Recht umgewandelt, $7.75 Bargeld pro Aktie zu erhalten, ohne Zinsen und vorbehaltlich der anwendbaren Quellensteuer.

Die Einreichung zeigt, dass die Position der Stammaktien der meldenden Person nach der Transaktion in 0 Aktien im Eigentum befindlich geändert wurde. Die Transaktion spiegelt die Mechanik der Aktienumwandlung zum Closing wider; das Unternehmen wurde zu einer hundertprozentigen Tochtergesellschaft von Continental Buyer, Inc.

Performant Healthcare (PHLT): مدير Form 4 مرتبط بالتصفية النقدية من خلال الاندماج. أبلغ مدير الشركة عن معاملة بتاريخ 21/10/2025 فيما يتعلق بإغلاق الاندماج بموجب اتفاقية الاندماج المؤرخة 31 يوليو 2025. قبل الوقت الفعّال مباشرة، تم إلغاء كل سهم عادي من Performant وتحويله إلى حق تلقي $7.75 نقداً للسهم، بدون فائدة وتخضع للضرائب المقتطعة المطبقة.

المستند يبين أن مركز الأسهم العادية للمبلغ عنه انتقل إلى 0 أسهم مملوكة من بعد المعاملة. الحدث يعكس آلية تحويل الأسهم عند الإغلاق؛ أصبحت الشركة شركة تابعة مملوكة بالكامل لـ Continental Buyer, Inc.

Positive
  • None.
Negative
  • None.

Performant Healthcare (PHLT): Direttore Form 4 legato al liquidamento dell'acquisizione. Un amministratore della società ha riportato una operazione datata 21/10/2025 in relazione alla chiusura della fusione ai sensi dell'accordo di fusione del 31 luglio 2025. Immediatamente prima dell'orario effettivo, ogni azione comune di Performant è stata annullata e convertita nel diritto a ricevere $7.75 per azione, senza interessi e soggetto a ritenute fiscali applicabili.

La dichiarazione mostra che la posizione azionaria comune del soggetto che riporta è passata a 0 azioni possedute beneficiariamente dopo la transazione. L'evento riflette la meccanica di conversione delle azioni al momento della chiusura; la società è diventata una filiale interamente controllata di Continental Buyer, Inc.

Performant Healthcare (PHLT): Director Form 4 vinculado al cobro en efectivo de la fusión. Un director de la empresa reportó una transacción con fecha 21/10/2025 relacionada con el cierre de la fusión bajo el Acuerdo de Fusión del 31 de julio de 2025. Inmediatamente antes de la hora efectiva, cada acción común de Performant fue cancelada y convertida en el derecho a recibir $7.75 en efectivo por acción, sin intereses y sujeto a las retenciones fiscales correspondientes.

El informe muestra que la posición de acciones comunes de la persona reportante pasó a 0 acciones beneficiosamente poseídas tras la operación. El evento refleja la mecánica de conversión de acciones en el cierre; la empresa se convirtió en una filial 100% de Continental Buyer, Inc.

Performant Healthcare (PHLT): 이사 Form 4가 합병 현금화와 연결됨. 한 회사 이사는 2025년 10월 21일자로 합병 체결에 따른 거래를 보고했습니다. 2025년 7월 31일 합병 계약에 따라. 유효 시점 직전, Performant 보통주의 모든 주식은 취소되어 주당 $7.75 현금 수령 권리로 전환되며 이자는 없고 해당 원천징수세의 적용을 받습니다.

보고서는 보고자의 보통주 포지션이 거래 후 소유 주식 0주로 이동했음을 보여줍니다. 이 이벤트는 종가 시 주식 전환 메커니즘을 반영합니다; 회사는 Continental Buyer, Inc.의 완전한 자회사가 되었습니다.

Performant Healthcare (PHLT) : Formulaire 4 du directeur lié au rachat par fusion. Un administrateur de la société a déclaré une opération datée du 21/10/2025 dans le cadre de la clôture de la fusion sous l'accord de fusion du 31 juillet 2025. Juste avant l'heure effective, chaque action ordinaire de Performant a été annulée et convertie en droit de recevoir $7.75 en espèces par action, sans intérêts et sous réserve des impôts à la source applicables.

Le dépôt montre que la position d'actions ordinaires de la personne déclarant est passée à 0 actions détenues par le bénéficiaire après la transaction. L'événement reflète les mécanismes de conversion des actions à la clôture; la société est devenue une filiale en propriété exclusive de Continental Buyer, Inc.

Performant Healthcare (PHLT): Direktor Form 4 im Zusammenhang mit Barabfindung bei Fusion. Ein Vorstand des Unternehmens meldete eine Transaktion datiert auf den 21.10.2025 im Zusammenhang mit dem Abschluss der Fusion gemäß dem Fusionsabkommen vom 31. Juli 2025. Unmittelbar vor dem Wirksamkeitszeitpunkt wurde jede Stammaktie von Performant storniert und in das Recht umgewandelt, $7.75 Bargeld pro Aktie zu erhalten, ohne Zinsen und vorbehaltlich der anwendbaren Quellensteuer.

Die Einreichung zeigt, dass die Position der Stammaktien der meldenden Person nach der Transaktion in 0 Aktien im Eigentum befindlich geändert wurde. Die Transaktion spiegelt die Mechanik der Aktienumwandlung zum Closing wider; das Unternehmen wurde zu einer hundertprozentigen Tochtergesellschaft von Continental Buyer, Inc.

Performant Healthcare (PHLT): مدير Form 4 مرتبط بالتصفية النقدية من خلال الاندماج. أبلغ مدير الشركة عن معاملة بتاريخ 21/10/2025 فيما يتعلق بإغلاق الاندماج بموجب اتفاقية الاندماج المؤرخة 31 يوليو 2025. قبل الوقت الفعّال مباشرة، تم إلغاء كل سهم عادي من Performant وتحويله إلى حق تلقي $7.75 نقداً للسهم، بدون فائدة وتخضع للضرائب المقتطعة المطبقة.

المستند يبين أن مركز الأسهم العادية للمبلغ عنه انتقل إلى 0 أسهم مملوكة من بعد المعاملة. الحدث يعكس آلية تحويل الأسهم عند الإغلاق؛ أصبحت الشركة شركة تابعة مملوكة بالكامل لـ Continental Buyer, Inc.

Performant Healthcare (PHLT): 董事 Form 4 关联并购现金结算。 一名公司董事在2025年10月21日报告了一笔交易,与按照2025年7月31日的并购协议进行的并购收盘有关。在生效时间之前,每股 Performant 普通股被取消并转换为获得$7.75现金、不计利息并需缴纳适用预扣税。

该披露显示举报人持有的普通股头寸在交易后变为0股被受益所有。该事件反映了收盘时的股权转换机制;公司成为 Continental Buyer, Inc. 的全资子公司。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Im Lisa

(Last) (First) (Middle)
4309 HACIENDA DR SUITE 110

(Street)
PLEASANTON CA 94588

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Performant Healthcare Inc [ PHLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share 10/21/2025 D(1)(2) 1,229,413 D (2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Pursuant to the Agreement and Plan of Merger, dated July 31, 2025 (the "Merger Agreement"), by and among Performant Healthcare, Inc. ("Performant" or "Company"), Continental Buyer, Inc., a Delaware corporation ("Continental" or "Parent") and Prevail Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Continental ("Merger Sub"), pursuant to which Merger Sub will be merged with and into Performant, with Performant surviving the merger as a wholly-owned subsidiary of Continental (the "Merger").
2. Effective as of immediately prior to the Effective Time (as defined in the Merger Agreement), each share of the Company's Common Stock, par value $0.0001 per share, as the "Common Stock" or "Company Shares" issued and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive $7.75 in cash without interest (the "Merger Consideration") subject to any applicable withholding taxes as provided in the Merger Agreement.
Remarks:
/s/ Rohit Ramchandani, Attorney-in-Fact for Lisa C. Im 10/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Performant Finl Corp

NASDAQ:PHLT

PHLT Rankings

PHLT Latest News

PHLT Latest SEC Filings

PHLT Stock Data

623.41M
72.54M
8.16%
92.51%
11.43%
Health Information Services
Services-miscellaneous Business Services
Link
United States
PLANTATION